tiprankstipranks
Trending News
More News >
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
US Market

VYNE Therapeutics (VYNE) AI Stock Analysis

Compare
1,845 Followers

Top Page

VY

VYNE Therapeutics

(NASDAQ:VYNE)

Rating:52Neutral
Price Target:
$1.50
▲(8.70%Upside)
VYNE Therapeutics' overall stock score is primarily affected by its weak financial performance and challenging valuation metrics. The financial struggles overshadow the mixed technical indicators, resulting in a lower overall score. Investors should be cautious due to the company's ongoing unprofitability and cash flow issues, despite low leverage risks.
Positive Factors
Efficacy in Psoriasis
All subjects receiving VYN202 showed improvements in key signs and symptoms of disease, including scalp psoriasis.
Safety and Efficacy
No patients experienced any serious side effects, and no patients had to discontinue or interrupt treatment because of any treatment-emergent side effects.
Vitiligo Treatment Advancements
Repibresib's previous Phase 1b results suggest greater efficacy at an earlier time point compared to the only approved vitiligo therapy, Opzelura.
Negative Factors
Clinical Hold
The FDA has placed a clinical hold on the Phase Ib study evaluating VYN202 due to testicular toxicity observed in dogs.
Study Suspension
The company has suspended all screening, enrollment, and dosing in the VYN202 study and is working with the FDA to resolve the hold.

VYNE Therapeutics (VYNE) vs. SPDR S&P 500 ETF (SPY)

VYNE Therapeutics Business Overview & Revenue Model

Company DescriptionVYNE Therapeutics (VYNE) is a biopharmaceutical company focused on developing and commercializing innovative therapies for dermatology and other therapeutic areas. The company specializes in leveraging its proprietary molecule technology to create treatments that address unmet medical needs. VYNE's core products include topical treatments for acne and other dermatological conditions, with a strong emphasis on research and development to expand its pipeline.
How the Company Makes MoneyVYNE Therapeutics generates revenue primarily through the commercialization of its dermatology products. The company earns money by selling its pharmaceutical treatments to healthcare providers, pharmacies, and distributors. Additionally, VYNE may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to expand the market reach of its products, which can provide additional revenue streams through upfront payments, royalties, or milestone payments. The company's focus on research and development also positions it to potentially benefit from future product launches and innovations in its therapeutic areas.

VYNE Therapeutics Financial Statement Overview

Summary
VYNE Therapeutics is struggling financially with declining revenue, negative profitability margins, and ongoing cash flow issues. While the balance sheet shows low leverage, consistent losses and negative cash flow raise concerns about financial sustainability.
Income Statement
40
Negative
VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.
Balance Sheet
55
Neutral
The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.
Cash Flow
45
Neutral
Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue605.00K501.00K424.00K477.00K14.76M20.99M
Gross Profit605.00K501.00K424.00K477.00K11.41M19.60M
EBITDA-44.45M-43.63M-29.26M-34.22M-38.94M-251.09M
Net Income-42.20M-39.83M-28.45M-33.95M-73.33M-255.57M
Balance Sheet
Total Assets56.42M66.91M97.69M40.76M67.05M93.74M
Cash, Cash Equivalents and Short-Term Investments50.27M61.52M93.25M30.91M42.25M58.59M
Total Debt63.00K99.00K214.00K-349.00K349.00K34.78M
Total Liabilities12.29M14.82M8.95M9.56M18.41M56.25M
Stockholders Equity44.13M52.09M88.73M31.20M48.64M37.49M
Cash Flow
Free Cash Flow-37.57M-34.09M-25.34M-29.20M-56.37M-137.19M
Operating Cash Flow-37.45M-33.97M-25.34M-29.20M-56.37M-137.08M
Investing Cash Flow46.77M23.36M-57.35M15.67M1.03M89.11M
Financing Cash Flow-224.00K-141.00K82.39M1.65M39.78M61.81M

VYNE Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.38
Price Trends
50DMA
1.19
Positive
100DMA
1.59
Negative
200DMA
2.10
Negative
Market Momentum
MACD
0.10
Negative
RSI
54.60
Neutral
STOCH
39.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Neutral. The current price of 1.38 is above the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.19, and below the 200-day MA of 2.10, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 54.60 is Neutral, neither overbought nor oversold. The STOCH value of 39.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VYNE.

VYNE Therapeutics Risk Analysis

VYNE Therapeutics disclosed 63 risk factors in its most recent earnings report. VYNE Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

VYNE Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$21.50M-66.15%43.03%81.75%
52
Neutral
$7.45B0.30-61.93%2.28%16.62%1.04%
50
Neutral
$45.35M-1205.58%203.23%13.57%
48
Neutral
$34.76M-1738.36%-43.55%69.81%
41
Neutral
$35.16M-853.05%34.97%
40
Underperform
$21.24M597.53%88.13%92.45%
30
Underperform
$50.14M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VYNE
VYNE Therapeutics
1.38
-0.58
-29.59%
PLUR
Pluri
5.56
-0.24
-4.14%
DARE
Daré Bioscience
2.40
-0.73
-23.32%
CLNN
Clene
3.80
-1.65
-30.28%
PYPD
PolyPid
3.43
-0.57
-14.25%
NRSN
Neurosense Therapeutics Ltd.
2.09
1.16
124.73%

VYNE Therapeutics Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
VYNE Therapeutics Sees Strong Shareholder Support for Growth
Positive
Dec 12, 2024

VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025